Tharimmune, Inc. — Director's Dealing 2022

Jan 18, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Hillstream BioPharma Inc. (HILS)
CIK: 0001861657
Period of Report: 2022-01-14

Reporting Person: Mazur Leonard L (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-14	Common Stock	C	98733	$3.20	Acquired	98733	Direct
2022-01-14	Common Stock	P	25000	$4	Acquired	123733	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-01-14	Convertible Note	$3.20	C		Disposed		Common stock (98733)	Direct

Footnotes

F1: On December 22, 2020, the Registrant issued the Reporting Person a $300,000 note which matures on the earlier of (i) December 31, 2023 and (ii) the closing of the Next Equity Financing. The note shall automatically convert into the type of Equity Securities issued in the Next Equity Financing. Pursuant to the terms of the note, because the Registrant's initial public offering qualified as a Next Equity Financing, the note automatically converted into shares of the Registrant's common stock. "Next Equity Financing" means the next sale (or series of related sales) by the Registrant of its Equity Securities pursuant to which the Registrant receives gross proceeds of not less than $7.5 million (inclusive of the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of notes). "Equity Securities" means, subject to certain exceptions, the Registrant's common stock and common stock equivalents.